Genoskin has announced the release of its ISR platform, the latest pre-clinical toolbox for studying injection site reactions (ISR) in humans before clinical trials.
FREMONT, CA: Genoskin, a biotechnology firm that develops transformative platforms and tools for testing therapeutic and non-therapeutic products on human skin, announces the release of its ISR platform, the latest pre-clinical toolbox for studying injection site reactions (ISR) in humans before clinical trials. To safeguard its transformative platform around the world, the business has filed intellectual property. Genoskin's ISR platform can help develop safer novel biologics by identifying mast cell-dependent (pseudo-allergy) and mast cell-independent inflammatory skin adverse events. Clients from all over the world can use the platform immediately.
Subcutaneous injected biologics have become a primary priority in the pharmaceutical business due to lower costs, shorter administration times that result in higher therapy compliance, and the possibility of additional patent protection for the sponsor while changing the route of administration. But this approach is also not without risks: patients frequently report mild to severe reactions at the injection site, such as swelling, erythema, pruritus, or discomfort. Injection site reaction, the most common side effect of biologics, can occur with all of them. The present shortage of research tools for studying injections in humans makes developing such medicinal compounds extremely difficult, especially when animal testing is the only alternative for companies.
"Imagine the possibilities now that we can characterize what happens in a human without using an actual patient. Our biotech and pharma clients can save time and reduce costs while securing their drug development," said Pascal Descargues, Ph.D., CEO of Genoskin. "As a partner research organization with strong expertise in skin physiology, human immunology and cell-based assays, our aim is to transform how drugs are developed today by reducing the high attrition rate in clinical development, thus increasing the number of available therapeutic options for patients. We are in a continued innovation process, heavily investing in our R&D, and are preparing for a new funding round to support our rapidly growing development."